{"id":"aricept-donepezil-sr-23-mg","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Vomiting"},{"rate":"5-10","effect":"Muscle cramps"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Insomnia"},{"rate":"2-3","effect":"Syncope"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting acetylcholinesterase, donepezil prevents the degradation of acetylcholine, leading to increased cholinergic neurotransmission in the central nervous system. This enhancement of acetylcholine signaling helps improve cognitive function and memory in patients with Alzheimer's disease. The sustained-release (SR) 23 mg formulation provides extended drug delivery over 24 hours.","oneSentence":"Donepezil is an acetylcholinesterase inhibitor that increases acetylcholine levels in the brain by blocking the enzyme that breaks it down.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:58.226Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate Alzheimer's disease"},{"name":"Moderate to severe Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT00566501","phase":"PHASE3","title":"Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-12-14","conditions":"Alzheimer's Disease","enrollment":915},{"nctId":"NCT01276353","phase":"PHASE2","title":"A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-01","conditions":"Alzheimer's Type Dementia","enrollment":45},{"nctId":"NCT00478205","phase":"PHASE3","title":"Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-06","conditions":"Alzheimer's Disease","enrollment":1467}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Donepezil hydrochloride"],"phase":"phase_3","status":"active","brandName":"Aricept (donepezil SR 23 mg)","genericName":"Aricept (donepezil SR 23 mg)","companyName":"Eisai Inc.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Donepezil is an acetylcholinesterase inhibitor that increases acetylcholine levels in the brain by blocking the enzyme that breaks it down. Used for Mild to moderate Alzheimer's disease, Moderate to severe Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}